Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 3/20 | 0.54 |
| ▸ | MC5R | P33032 | 2/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760892 | 0.84 | CYP19A1 (0.70) | MC1RMC5RMC3RCYP19A1MEN1 | |
| SCHEMBL19410682 | 0.82 | ALOX12 (0.62) | CYP19A1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25252806 | 0.81 | CYP19A1 (0.74) | MC1RMC5RMC3RCYP19A1 | |
| SCHEMBL25241467 | 0.80 | CYP19A1 (0.50) | MC1RMC5RMC3RCYP19A1 | |
| SCHEMBL25247387 | 0.80 | NR3C1 (0.66) | CYP19A1MEN1KMT2AMAPTCYP3A4 | |
| SCHEMBL1851985 | 0.78 | KMT2A (0.58) | GPR84CYP19A1MEN1KMT2AMAPT | |
| SCHEMBL29350522 | 0.78 | HTR2A (0.69) | MC1RMC5RMC3RGPR84MEN1 | |
| SCHEMBL1092334 | 0.78 | HTR2A (0.69) | MC1RMC5RMC3RGPR84MEN1 | |
| SCHEMBL25247095 | 0.77 | MGAM (0.52) | MC1RMC5RMC3RGPR84CYP19A1 | |
| SCHEMBL25244099 | 0.77 | CYP19A1 (0.60) | CYP19A1MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250093329-A1 | SCREENING OF COMPOUNDS | THE UNIVERSITY OF TULSA | 2025-03-20 | — | — | US | disclosed |
| US-20230266302-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | THE UNIV OF TULSA (US) | 2023-08-24 | — | — | US | disclosed |
| EP-4185706-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | The University Of Tulsa (US) | 2023-05-31 | — | — | EP | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | MC1R 1148/4885MC5R 1446/4885MC3R 1154/4885 |
| US-20230266302-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | ATP5ME, ATP5F1B, ATP5MG | MC1R 4670/4885MC5R 4786/4885MC3R 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.